Company ProfilePremium

Ping An Biomedical Co. Ltd.

Company Profile Analysis

Ticker: PASW平安生物医药有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ping An Biomedical Co. Ltd. - Company showcase

Year Founded & Workforce

2013

7 Employees

Ping An Biomedical Co. Ltd. logo

Ping An Biomedical Co. Ltd. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ping An Biomedical Co. Ltd. Overview

Ping An Biomedical is a Cayman-domiciled, Hong Kong-headquartered micro-cap that today operates a small, asset-light apparel supply-chain management (SCM) business in mainland China through its Shanghai subsidiary New Brand. That business sources and resells cashmere, wool, cotton and fancy yarns and, to a lesser degree, finished knitwear, coordinating third-party mills and contract manufacturers for brand owners, textile manufacturers, sourcing agents and online retailers. Revenue fell 61% in FY2025 to RMB34.1 million and declined a further 47% year-on-year in the first half of FY2026. Following its July 2025 IPO, a change of control-style leadership overhaul in October 2025, and a highly dilutive US$0.04-per-share placement in February 2026, management has rebranded the company toward biomedical and health technologies, signing a non-binding memorandum to invest in Future Biotechnology Group and a channel agreement in health services. The equity trades well below Nasdaq's US$1 minimum bid, with a compliance deadline of November 23, 2026.


Company's own description

In its FY2025 Form 20-F, the company describes itself as a holding company conducting operations through its PRC subsidiary New Brand, positioned as a provider of SCM services in the apparel industry offering one-stop solutions across yarn products, textiles and finished garments. The service scope covers market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The 20-F explicitly characterizes the model as "asset-light": substantially all products are produced by third-party contract manufacturers using raw materials the company sources from vendors, and the company holds ownership in only a very limited number of proprietary apparel products [Source: 20-F FY2025, Risk Factors].

The September 2025 rebranding press release added that the new name reflects a strategic focus on biomedical and healthcare technologies [Source: GlobeNewswire, September 12, 2025]. StockTitan's issuer profile now describes the company both as an apparel SCM provider and as focused on healthcare and biomedical technology.

Business model and revenue model

DimensionCharacterization
Revenue typeProduct sales (100%): sales of yarns and finished garments recognized at a point in time when goods are accepted by the customer [Source: 6-K H1 FY2026, Note 2]
Service vs. productEconomically a service (sourcing/coordination) business, but monetized through product resale margins rather than fees
Subscription / licensingNone disclosed
Payment termsCustomers typically pay within 40 to 90 days; goods deemed accepted if not returned within 15 days [Source: 6-K H1 FY2026]
Capital intensityMinimal: gross PP&E of RMB99,255 (computer and office equipment) at September 30, 2025 [Source: XBRL, 20-F FY2025]
Gross margin profileThin: 5.1% (FY2023), 6.2% (FY2024), 2.8% (FY2025), 7.5% (H1 FY2026)
SeasonalityFinished garments peak August to December; yarns show no clear seasonality [Source: 20-F FY2025]

Value chain position

The company sits between upstream fiber/yarn spinners and downstream garment producers or brand owners. It does not spin, knit or dye. Its value-add is trend interpretation, design, supplier selection, quality control and logistics coordination. This "middleman" position is structurally exposed to disintermediation; the 20-F itself notes brand owners increasingly order directly from manufacturers via online platforms.

Customer types and end markets

Customers span brand owners, textile manufacturers, apparel sourcing agents, and online fashion and garment retailers [Source: Renaissance Capital IPO profile]. Concentration is extreme: the top five customers accounted for 81% of revenue in FY2023, 86% in FY2024 and 91% in FY2025 [Sources: Renaissance Capital, October 2024; 20-F FY2025]. In H1 FY2026, the top three customers contributed 31.72%, 24.43% and 14.20% of revenue [Source: 6-K H1 FY2026]. All revenue is generated in the PRC (the company's definition of "China" includes Hong Kong).

Independent characterization

On the evidence of the filings, PASW is best characterized as a sub-scale yarn trading intermediary in structural decline, now serving primarily as a listed vehicle for a strategic pivot whose substance has not yet been demonstrated. Three facts support this view. First, revenue contracted from RMB87.6 million (FY2024) to RMB34.1 million (FY2025) to an annualized run-rate of roughly RMB19 million (H1 FY2026 doubled). Second, the H1 FY2026 return to profit was driven entirely by a RMB6.09 million credit-loss reversal and a RMB5.67 million fair-value gain on a listed equity investment; the core business generated only RMB0.54 million of operating income including that reversal, implying an underlying operating loss of about RMB5.5 million. Third, the "biomedical" business has no disclosed revenue, products, regulatory approvals or staff; its WFOE (Pingyuan Anjian Biotech (Hainan) Co., Ltd) was described as having no operations as of the H1 FY2026 report.

Strategy

Stated strategy themes

From the IPO-era materials and 20-F: (i) procure raw materials for textile and garment manufacturing; (ii) broaden the customer base; (iii) enhance efficiency and SCM capabilities; (iv) explore eco-friendly and sustainable raw materials; (v) broaden the sourcing chain; and (vi) fund working capital. These were the stated uses of IPO proceeds [Source: IPO closing press release, July 22, 2025].

From September 2025 onward, management's messaging shifted to biomedical and healthcare technologies, emphasizing corporate image and positioning in the industry [Source: press release, Sep 12, 2025]. No investor day has been held and no formal strategic plan document has been published.

Initiatives in the last 24 months

DateInitiativeDetailStatus
Jul 2025IPOUS$15.0M gross raisedCompleted
Aug 2025Hainan biotech WFOEPingyuan Anjian Biotech formedDormant
Sep 2025RebrandPing An Biomedical name and PASW tickerCompleted
Nov 2025Equity investmentsDirect Booking Technology, Zhi Ding Group, Lanzhi Yunchuang Technology; RMB29.1M deployed by March 2026Completed (carrying value RMB41.25M)
Jan 2026Future Biotechnology Group memorandumUS$30M initial cash investment plus up to US$60M follow-on acquisitions (cash and escrowed consideration shares)Non-binding
Jan–Mar 2026Equity raises100M shares at US$0.04; 567,000 at US$0.15Completed
Mar 2026Capital restructuringDual-class shares; share consolidation authority (StockTitan summary cites a conditional 1,000:1 ratio; press release leaves ratio to board)Approved; consolidation not yet effected as of latest filing
Jul 2026Trademark acquisitionUS$2.5M Hong Kong marks from related partyCompleted
Jul 2026Health channel partnershipYuan Sheng Mei Yan; RMB500M three-year cumulative sales targetSigned

Guidance and targets

No revenue, margin or earnings guidance has been issued. The only quantified forward targets relate to counterparties: Future Biotechnology Group revenue thresholds of RMB750 million (2026), RMB1.3 billion (2027) and RMB2.3 billion (2028) govern escrow release, and the Yuan Sheng Mei Yan agreement targets RMB500 million cumulative sales over three years. Note the scale mismatch: the Future Biotechnology initial investment alone (US$30 million) is roughly double PASW's market capitalization and about six times its March 31, 2026 unrestricted plus restricted cash (about US$5.2 million). Funding sources for that commitment have not been disclosed.

ESG commitments and cost programs: none disclosed.

Products & Services

Apparel SCM (the only revenue-generating activity)

OfferingDescriptionTarget customerLaunch / statusPricing model
Cashmere and cashmere-blend yarnsSourced from third-party spinners and resold; the company's legacy specialty (New Brand's name references cashmere)Knitwear manufacturers, brand ownersSince 2014Per-order fixed price; vendor cost agreed concurrently with customer order
Merino wool yarnsSourced fine-wool yarnsKnitters, garment makersSince 2014Per-order
Cotton yarnsCommodity and specialty cotton yarnsGarment makers—Per-order
Fancy yarnsNovelty and textured yarnsFashion knitwear producers—Per-order
Silk inputsListed among raw materials———
Finished garments (knitwear)End-to-end coordination from trend analysis and design to contract manufacturing, QC and deliveryBrand owners, sourcing agents, online retailersSince 2014Per-order
Market trend analysisBundled serviceAll customersNot separately pricedEmbedded in product margin
Product design and developmentIn-house design capabilityBrand ownersNot separately pricedEmbedded
Raw material sourcingSupplier selection and procurementAllNot separately pricedEmbedded
Production and quality controlInspection and rectification of contract outputGarment customersNot separately pricedEmbedded
Logistics managementDelivery coordinationAllNot separately pricedEmbedded

Named flagship brands: none disclosed. The company states it owns very few proprietary apparel products. The trademarks acquired in July 2026 (Hong Kong, US$2.5M, from Meridian Industries) are listed in a deed schedule; the specific marks were not visible in the filed exhibit.

Biomedical / health (announced, pre-revenue)

InitiativeDescriptionStatusSource
Pingyuan Anjian Biotech (Hainan)WFOE vehicle for biotech activitiesNo operations disclosed6-K H1 FY2026
Future Biotechnology Group investmentTarget described as engaged in biopharmaceutical R&D, genetic testing, medical devices and pharmaceutical salesNon-binding memorandum onlyPress release, Jan 9, 2026
Yuan Sheng Mei Yan channel partnershipPASW to supply biotechnology products and technical support; partner provides health-management and wellness channelsAgreement signed; no revenue disclosed6-K, Jul 22, 2026
Biotechnology product catalog—No products, specifications or approvals disclosed—

Note on third-party descriptions: Several low-quality syndicated websites describe PASW as an in-vitro diagnostics and precision-medicine company. No SEC filing reviewed supports that description, and it is disregarded here.

Financial Narrative

Coverage limitation: The company listed in July 2025, and its 20-F presents three years (FY2023–FY2025) of income and cash-flow data and two balance sheets (FY2024–FY2025). Tables therefore cover FY2023–FY2025 plus the H1 FY2026 interim period.

Income statement (RMB)

Sources: SEC XBRL company facts for the FY2025 20-F. Selling expenses derived as total operating expenses minus G&A minus credit loss provision. Tax sign convention normalized (expense positive). FY2025 EPS in USD was -0.10.

Margins and growth (%)

Revenue CAGR FY2023–FY2025: -35.7% per year (analyst calculation).

Interim comparison (six months ended March 31, RMB)

Source: 6-K H1 FY2026.

Commentary — income statement. FY2024 represented the high-water mark of a very low-margin model: revenue grew 6.1% to RMB87.6 million, but G&A rose 53% to RMB5.0 million (IPO preparation costs and listing readiness), wiping out operating income. FY2025 is the inflection: revenue collapsed 61% (H1 alone fell 60% year-on-year, from RMB45.7 million to RMB18.2 million), gross margin halved, and a RMB9.34 million credit-loss charge was taken as the allowance on receivables rose from RMB11.04 million to RMB15.16 million against gross receivables of RMB32.09 million (47% reserved). The deferred tax benefit of RMB1.86 million partially cushioned the result.

H1 FY2026 shows a reported swing to RMB4.83 million net income, but analysis of quality is essential. Removing the RMB6.09 million credit-loss reversal and RMB5.67 million fair-value gain yields an underlying pre-tax loss of approximately RMB5.48 million on revenue of RMB9.59 million. G&A rose 71% year-on-year to RMB4.54 million, including RMB1.44 million of amortized stock compensation from consultant options; selling expenses rose more than tenfold to RMB1.73 million despite halving sales, plausibly reflecting biomedical business development costs (not explained in the filing).

Balance sheet (RMB)

Sources: XBRL for 20-F FY2025; FY2025 line items confirmed against comparative column in 6-K H1 FY2026. Restricted cash at FY2024 derived as nil (total cash and restricted cash equaled unrestricted cash of RMB130,923).

Source: 6-K H1 FY2026.

Commentary — balance sheet. The IPO (US$15.2 million recorded as proceeds; RMB108.2 million gross in XBRL) transformed a negative-equity balance sheet into RMB45.2 million of equity. However, the cash was overwhelmingly restricted (RMB35.5 million of RMB36.7 million), and the reason for the restriction is not explained in the reviewed sources. By March 31, 2026, RMB29.1 million of cash had been deployed into equity investments (Direct Booking Technology Co., Ltd, a listed investee; Zhi Ding Group Co Limited; and Lanzhi Yunchuang Technology (Beijing) Co., Ltd). Equity investments now represent 41% of total assets, meaning reported book value is increasingly a function of investee valuations rather than operating assets. The carrying value of RMB41.25 million exceeds cash outlay plus fair-value gain (RMB34.80 million) by about RMB6.45 million; the reconciling item is not disclosed in reviewed material.

Cash flow (RMB)

Sources: XBRL. Capex inferred as nil because gross PP&E was unchanged at RMB99,255 between September 30, 2024 and September 30, 2025. FY2025 income taxes paid not disclosed in XBRL; shown as 0 for charting only.

H1 FY2026: operating cash flow RMB1.14 million; investing outflow RMB29.13 million (equity investments); financing inflow RMB28.41 million (share issuance RMB28.62 million; related-party loans RMB10.80 million drawn and RMB11.01 million repaid) [Source: 6-K H1 FY2026].

Commentary — cash flow. Operating cash flow is dominated by working-capital swings in receivables and payables rather than earnings. FY2024's positive RMB14.6 million OCF was largely a release of prepayments and payables timing, used along with investing inflows to repay RMB30.1 million of financing. The business has never been capital intensive. The defining cash-flow feature since listing is that external equity (IPO and placements) has been redeployed into minority equity stakes and a related-party trademark purchase rather than into the operating business.

Ratios

Analyst calculations from XBRL data. FY2024 ROE and ROIC shown as 0 because equity was negative (not meaningful). FY2025 ROIC approximated as after-tax operating loss (operating loss less 25% statutory tax) over equity plus borrowings. Net debt/EBITDA not meaningful in both years (FY2025 net cash; negative EBITDA).

Interpretation. Receivable days of 170–180 days in a business with contractual terms of 40–90 days indicate chronic collection problems, consistent with the 47% allowance. Payables stretched to over 100 days in FY2025, suggesting the company leaned on suppliers as revenue contracted.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityJurisdictionOwnershipFunction

Ping An Biomedical Co., Ltd.

Cayman Islands

Listed parent

Holding company

Nifty Holdings Limited

BVI

100% by parent

Investment holding

Multi Ridge (Asia) Limited

Hong Kong

100% by Nifty

Investment holding; purchaser of trademarks (July 2026)

New Brand Cashmere Products Co., Ltd

PRC (Shanghai)

100% by Multi Ridge

Operating company: trading of yarns and finished garments

Pingyuan Anjian Biotech (Hainan) Co., Ltd

PRC (Hainan)

100% by Multi Ridge

Established August 27, 2025; no operations as of H1 FY2026 report

Segment / Product Line Details

Segment / product lineContentsProducts

Sales of Yarns

Sourcing and resale of yarns to knitters and garment makers

Pure cashmere and cashmere-mix yarns, merino wool, cotton, fancy yarns

Sales of Finished Garments

Design-to-delivery coordination of knitwear produced by contract manufacturers

Knitwear and finished garments for brand owners and online retailers

Product Lines

Product line (H1 FY2026, six months to Mar 31, 2026)Revenue (CNY Mn)% of total

Sales of Yarns

8.8492

Sales of Finished Garments

0.768

Total

9.59100

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Total revenue (CNY Mn)

82.5687.6234.15

YoY growth (%)

06.1-61.0

Gross profit (CNY Mn)

4.245.420.95

Gross margin (%)

5.16.22.8

Income Statement (CNY) and Per-Share Data

Metric (MYR Bn)FY2023FY2024FY2025

Revenue

82,563,75187,622,39534,147,936

Cost of revenue

78,323,58382,205,50833,198,431

Gross profit

4,240,1685,416,887949,505

Selling expenses (derived)

332,508306,582299,959

General and administrative expenses

3,265,3414,992,4816,007,792

Credit loss provision

29,838119,8639,343,225

Total operating expenses

3,627,6875,418,92615,650,976

Operating income (loss)

612,481-2,039-14,701,471

Depreciation

32,75610,2395,585

EBITDA (operating income plus depreciation)

645,2378,200-14,695,886

Interest expense

1,740,259705,273307,055

Interest income

156,1422,034326,349

Other non-operating income

1,013,322110,43541,966

Pre-tax income (loss)

41,686-682,716-14,684,795

Income tax expense (benefit)

1,035,623601,456-1,855,589

Net income (loss)

-993,937-1,284,172-12,829,206

EPS basic and diluted (MYR Bn)

-0.06-0.07-0.69

Dividends per share (MYR Bn)

000

Margin Analysis (%)

Metric (%)FY2023FY2024FY2025

Gross margin

5.146.182.78

Operating margin

0.740.00-43.05

EBITDA margin

0.780.01-43.04

Pre-tax margin

0.05-0.78-43.00

Net margin

-1.20-1.47-37.57

G&A as % of revenue

3.955.7017.59

Revenue growth YoY

06.13-61.03

Income Statement (CNY) and Per-Share Data (Half-Yearly)

Metric (MYR Bn)H1 FY2025H1 FY2026

Revenue

18,230,9639,594,250

Gross profit (loss)

-692,318723,357

Selling and marketing

151,3381,734,519

General and administrative

2,647,9924,537,652

Credit loss provision (reversal)

125,888-6,086,418

Operating income (loss)

-3,617,536537,604

Fair value gain on equity investment

05,673,782

Pre-tax income (loss)

-3,738,2416,283,707

Income tax expense

494,8781,457,734

Net income (loss)

-4,233,1194,825,973

EPS basic and diluted (MYR Bn)

-0.240.10

Weighted average shares

18,000,00050,530,258

Balance Sheet (CNY)

Metric (MYR Bn)FY2024FY2025

Total assets

56,849,75568,414,527

Current assets

53,310,11863,697,447

Cash and bank balances (unrestricted)

130,9231,172,480

Restricted cash

035,523,810

Accounts receivable, gross

51,483,12132,092,210

Allowance for credit losses

11,041,82515,161,334

Accounts receivable, net

40,441,29616,930,876

Deposits, prepayments and other receivables

12,603,3049,628,377

Inventories

127,296441,904

Deferred tax assets

2,722,2334,249,503

Goodwill and intangibles

00

Current liabilities

63,576,48323,076,822

Short-term bank borrowings

010,000,000

Accounts payable

15,055,8209,413,410

Total liabilities

64,037,93623,172,520

Shareholders' equity (deficit)

-7,188,18145,242,007

Working capital

-10,266,36540,620,625

Net debt (borrowings less cash incl. restricted)

0-26,696,290

Balance Sheet (CNY) (Mar 31, 2026)

Metric (MYR Bn)Mar 31, 2026

Total assets

100,222,250

Cash and bank balances

6,842,381

Restricted cash

29,144,050

Accounts receivable, net

6,188,887

Equity investments

41,246,798

Short-term bank borrowings

10,000,000

Other payables, related parties

3,037,926

Total liabilities

22,040,208

Shareholders' equity

78,182,042

Working capital

33,870,564

Cash Flow (CNY)

Metric (MYR Bn)FY2023FY2024FY2025

Operating cash flow

-6,082,83614,630,221-6,427,762

Investing cash flow

-3,367,57015,000,0000

Financing cash flow

8,874,664-30,088,90543,660,424

Interest paid

1,950,750705,274310,891

Income taxes paid (refunded)

2,124,332-220,8650

Cash Flow (CNY) (FY2024–FY2025)

Metric (MYR Bn)FY2024FY2025

Capital expenditure

00

Free cash flow (OCF less capex)

14,630,221-6,427,762

Dividends paid

00

Share buybacks

00

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE (net income / ending equity, %)

0-28.36

ROA (net income / ending assets, %)

-2.26-18.75

ROIC (%)

0-26.6

Current ratio (x)

0.842.76

Debt / equity (x)

00.22

Net debt / EBITDA (x)

00

Interest coverage, EBIT / interest (x)

0.00-47.88

Asset turnover, revenue / ending assets (x)

1.540.50

Days sales outstanding

168.5181.0

Days inventory outstanding

0.64.9

Days payables outstanding

66.8103.5

Cash conversion cycle (days)

102.382.4

Revenue by Region (%)

RegionFY2023FY2024FY2025

PRC including Hong Kong (% of revenue)

100100100

Rest of world (% of revenue)

000

Share Price & Returns

Reference pointPrice (USD)Source

IPO price (Jul 17, 2025)

6.00

Press release

First-day close (Jul 18, 2025)

3.30

IPOScoop

Jul 25, 2025 close

1.81

AlphaQuery

Oct 1, 2025

1.24

StockTitan

Apr 1, 2026

0.13

Seeking Alpha

Apr 14, 2026

0.16

Trendlyne

Aug 4, 2026

0.13

MarketChameleon

Sep 24, 2026

0.13

Benzinga

Metric

Value

—

Return since IPO price

Approximately -97.8% (analyst calculation, US$6.00 to US$0.13)

—

1-year return

Not meaningful / approximately -90% from Oct 1, 2025 level of US$1.24

—

3-year and 5-year returns

Not applicable (listed July 2025)

—

52-week range

US$0.11–US$1.32 (Benzinga, Sep 2026)

—

Beta

0.09 (MarketChameleon; low reliability given liquidity)

—

Average weekly volatility

About 30% (Simply Wall St)

—

Valuation Snapshot

MultipleValueBasis

Market capitalization (USD Mn)

16.3

125.117M shares

Enterprise value (USD Mn)

12.5

Market cap plus US$1.45M borrowings less US$5.22M cash and restricted cash (Mar 31, 2026)

EV/Sales (TTM)

About 3.4x

TTM revenue about RMB25.5M (about US$3.7M)

P/B

About 1.4x

Book equity US$11.33M at Mar 31, 2026

Capital Markets

ItemStatus

Analyst consensus

No sell-side coverage identified

Dividend policy

No intention to pay dividends in the near future (20-F)

Buyback authorizations

None, other than the approved repurchase-and-issue exchange with INSPIRETECH (non-cash)

Debt maturity profile

RMB10.0M short-term bank borrowings (Bank of China; XBRL tags reference May 19, 2026); still outstanding at March 31, 2026; current status post-May 2026 not disclosed

Equity issuance history

IPO 2.5M at US$6.00 (Jul 2025); 4.05M option shares to consultants (Nov 2025); 100M at US$0.04 (Feb 2026); 567,000 at US$0.15 (Mar 2026)

Authorized capital

US$312,500: 4.9B Class A and 100M Class B shares (post-AGM)

Pending consolidation

Board authority within one year of March 18, 2026; ratio at board discretion (StockTitan summary references 1,000:1 conditional)

Analyst Conclusions

Management guidance

None. Management stated in the H1 FY2026 report that existing resources are sufficient for at least 12 months of operations, while acknowledging macro and demand uncertainty. Consensus growth expectations: none (no coverage).

Bull case (grounded in data)

  1. Clean balance sheet with optionality: RMB78.2M of equity, net cash of about RMB26M including restricted cash, and a market capitalization of about US$16M mean the market pays a modest premium to book for a listed platform with recognized strategic investors.

  2. Credible upside if the Future Biotechnology deal becomes definitive: The escrow structure ties consideration shares to audited revenue of RMB750M in 2026 rising to RMB2.3B in 2028, with unearned tranches cancelled; if executed on those terms, PASW would acquire revenue many times its current scale with partial performance protection.

  3. Credit recovery and investment gains: H1 FY2026 already showed RMB6.09M of reserve reversals and a RMB5.67M investment gain; further collections and a rising listed investee could continue to support reported earnings and book value.

Bear case (grounded in data)

  1. Core business is disappearing: Revenue fell from RMB87.6M (FY2024) to an annualized ~RMB19M (H1 FY2026); underlying H1 FY2026 pre-tax loss of about RMB5.5M excluding one-offs.

  2. Shareholder-unfriendly capital actions: A placement at US$0.04 (versus a market price several times higher in the same period) increased the share count roughly fivefold; consultant options added 4.05M shares; a 100-vote Class B structure was approved for a holder of under 10% of economic interest; and US$2.5M was paid to a Controlling Shareholder-linked entity for trademarks of undisclosed specification.

  3. Listing and execution risk: The stock needs roughly an 8x price increase (or a large reverse split) by November 23, 2026; the Future Biotechnology memorandum remains non-binding and the US$30M initial commitment exceeds available cash several times over.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Nasdaq bid-price deadlineNov 23, 2026Announcement and ratio of share consolidation; Nasdaq panel request if missed
FY2026 Form 20-FBy end-January 2027 (120 days after Sep 30 FYE)First audit by Edston Global PAC; going-concern opinion; segment disclosure; equity investment valuations
Future Biotechnology GroupOngoingDefinitive agreement, funding source, CSRC filings, consideration share count
Yuan Sheng Mei Yan channelOngoingFirst biomedical revenue recognition; product identification and regulatory approvals
Class B issuanceOngoingWhether INSPIRETECH exchange is executed; resulting voting power
Related-party flowsOngoingFurther transactions with Meridian, Wisewing and other Controlling Shareholder entities
Bank borrowingsOngoingRenewal or repayment of RMB10M Bank of China facility
Equity investmentsSemi-annualMark-to-market of Direct Booking Technology and other investees
Resale registrationsOngoingSelling-holder supply overhang (13.61M shares reported)

Analyst verdict

Ping An Biomedical is, on the evidence available, a shell-like listed vehicle attached to a shrinking yarn-trading operation, now marketed as a biomedical platform. The apparel SCM business that justified the July 2025 IPO lost 61% of its revenue in the first full fiscal year of listing and almost half again in the following half-year, and it operates at gross margins that leave no room for a public-company cost base. The FY2025 audited loss of RMB12.8 million and the underlying H1 FY2026 loss of roughly RMB5.5 million, once credit-loss reversals and a single investment mark are stripped out, describe a business that does not earn its keep.

The investment case therefore rests entirely on the pivot and on capital allocation by a management team installed in October 2025. So far the record is concerning. Capital raised has gone into minority stakes in technology companies whose connection to biomedicine is unexplained, into a US$2.5 million trademark purchase from an entity controlled by a founding shareholder, and into stock compensation for consultants. The February 2026 placement at four US cents per share transferred roughly 80% of the company's economic ownership to unnamed private-placement investors at a deep discount, and the approved dual-class structure could concentrate over 90% of voting power in an entity linked to the CEO. The headline Future Biotechnology Group transaction remains a non-binding memorandum whose initial cash component alone dwarfs the company's resources.

Disclosure quality is also weak: stale risk-factor figures, a 6-K cover that mischaracterizes the counterparty to a related-party deal, an unexplained RMB35.5 million restricted-cash balance, and an unreconciled gap in equity investment carrying values.

Verdict: high risk, speculative, and not investable on fundamentals. Monitor only for a definitive, independently funded biomedical transaction, the outcome of the November 2026 Nasdaq deadline, and the first audit by the new auditor.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointedBornEducationPrior roles

Pijun Liu

Chairman, CEO, Executive Director

Oct 14, 2025

1,982

Bachelor's, Wuhan University of Technology; Master's in Computer and Information Technology, University of Arizona; postgraduate study at Renmin University School of Finance (2018–2020); Tsinghua EMBA program

Project manager at eLong.com (2004–2007); founder and CEO of Yueshang Group (2014–2023)

Hongli Yang

Chief Financial Officer

Oct 14, 2025

1,995

Bachelor's in Financial Management, Xiangtan University

CFO roles since 2021 at Softcom Information Technology (Group), Beijing Sinobo Information Technology, and Huibo Cloud Communication Technology; also a director of Multi Ridge (signatory to July 2026 deed)

Xianzhi Liu

Independent Director

Oct 14, 2025

1,997

Bachelor's in Electronic Science and Technology, North University of China; Master's in Mechatronics and Robotics, University of Leeds

JD.com (2022); Beijing New Oriental Education Consulting (2023–2024); New Channel, Zhejiang headquarters (2025–)

Board of Directors — Yuk Yin Judy Li

NameFormer roleDepartureStated reason

Yuk Yin Judy Li

Chair and Director (also a Controlling Shareholder)

October 2025

Personal reasons; no disagreement

Lina Jiang

CEO and Director

October 2025

Personal reasons; no disagreement

Xueyuan Chen

CFO

October 2025

Personal reasons; no disagreement

Taylor Carl Coplen

Independent Director

October 2025

Personal reasons; no disagreement

Governance Overview

AttributeStatus

Chair / CEO separation

Combined (Pijun Liu holds both roles)

Home-country practice exemptions

20-F states none currently relied upon

Dual-class structure

Approved March 18, 2026: 4.9 billion Class A and 100 million Class B authorized; StockTitan summary indicates Class B carries 100 votes per share

Insider trading policy, code of ethics

Adopted at IPO

Material weakness in ICFR

Disclosed (segregation of duties; governance)

Major Shareholders

HolderShares% of 125,117,000Source / note

INSPIRETECH LTD (indirect holding of CEO Pijun Liu)

12,250,0009.8

Form 3, April 8, 2026

Purchasers of 100,000,000-share private placement (accredited / Regulation S investors)

100,000,00079.9

6-K, Feb 12, 2026; individual allocations not disclosed

Purchasers of March 2026 placement

567,0000.5

6-K H1 FY2026

Six consultants (exercised options)

4,050,0003.2

6-K H1 FY2026; may since have been sold

IPO public float

2,500,0002.0

Prospectus

Institutional holders (13F)

—

Negligible

No material institutional ownership identified

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorSegment overlapPositioning relative to PASW

Shenzhou International Group (HKEX: 2313)

Knitwear manufacturing for global brands

Vertically integrated giant; incomparable scale

Crystal International Group (HKEX: 2232)

Apparel manufacturing and supply

Multinational manufacturer with brand-owner relationships

Texhong International (HKEX: 2678)

Yarn production

Large spinner; illustrates industry margin compression (yarn gross margin under 1% in H1 2023 per Benzinga)

Ordos / Erdos Resources (SSE: 600295)

Cashmere products

Integrated cashmere brand and processor

Consinee Group (private, Ningbo)

Cashmere and fine-wool yarns

Specialist spinner selling direct to knitters

Novetex Textiles (private, Hong Kong)

Yarn spinning

Direct supplier to knitters

Li & Fung (private since 2020)

Global sourcing and SCM

Category-defining sourcing intermediary

Addentax Group (Nasdaq: ATXG)

Garment manufacturing, logistics and related services in China

Comparable U.S.-listed China micro-cap

B2B online sourcing platforms (e.g., Alibaba 1688)

Direct manufacturer ordering

Primary disintermediation threat cited in 20-F

Peer Comparison FY2025

MetricPASW (FY2025)Texhong International

Revenue

RMB34.1M

—

Revenue growth

-61.0%—

Gross margin

2.8%

Low single digits in 2023 per Benzinga

Net margin

-37.6%

Loss-making in 2023 per Benzinga

R&D intensity

0%—

Company Snapshot

$4.7M

Revenue

7

Employees

$15.9M

Market Cap

2013

Founded

Kowloon, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Net cash balance sheet: Cash plus restricted cash of RMB35.99M against RMB10.0M of bank borrowings at March 31, 2026 [6-K H1 FY2026].
  • Positive equity: Shareholders' equity of RMB78.18M at March 31, 2026, up from a RMB7.19M deficit at September 30, 2024.
  • Asset-light model: Gross PP&E under RMB0.1M; no capex burden [XBRL].
  • Positive operating cash flow in H1 FY2026: RMB1.14M versus RMB0.25M a year earlier.
  • Nasdaq listing access: Demonstrated ability to raise equity (IPO plus about US$4.1M of placements within eight months).
  • Recognized strategic investors: Participation announced from executives linked to 58 Group, Amiba Capital and Magcloud Group (January 2026).

Weaknesses

  • Collapsing revenue: -61.0% in FY2025 and -47.4% in H1 FY2026.
  • Thin margins: Gross margin 2.8% in FY2025.
  • Earnings quality: H1 FY2026 profit relied on RMB11.76M of credit-loss reversal and fair-value gains.
  • Extreme concentration: Top five customers 91% of FY2025 revenue; one vendor 53.6% of H1 FY2026 purchases.
  • Receivables quality: 181 days sales outstanding and a RMB15.16M allowance (47% of gross receivables) at FY2025.
  • Internal control weaknesses: Material weaknesses disclosed in the 20-F; stale and internally inconsistent risk-factor text (net current liabilities misdated).
  • Micro staff base: 7–9 employees reported.

Opportunities

  • Biomedical pivot: Future Biotechnology Group targets imply a business with RMB750M+ revenue if a definitive deal closed on favorable terms.
  • Health channel agreement: RMB500M three-year sales target with Yuan Sheng Mei Yan.
  • Credit recovery: Further reversals possible if remaining reserved receivables (including the RMB11.5M Tianjin Xinfa claim) are collected.
  • Equity investment upside: Listed investee generated a RMB5.67M fair-value gain in one half-year.
  • Reverse split: Board authority to consolidate shares could restore Nasdaq compliance.
  • Trademark monetization: US$2.5M of acquired marks could support branded products, if deployed.

Threats

  • Nasdaq delisting: Must regain US$1 bid for 10 consecutive days by November 23, 2026; stock at about US$0.13.
  • Funding gap: US$30M initial Future Biotechnology commitment vs. about US$5.2M cash; would require heavy dilution or debt.
  • Dilution: Share count rose from 20.5M to 125.1M in six months; consideration shares contemplated.
  • Control concentration: Approved 100-vote Class B shares could give a sub-10% economic holder over 90% of votes.
  • Related-party cash outflows: US$2.5M trademark purchase from a Controlling Shareholder entity.
  • PRC regulatory risk: CSRC filing requirements for subsequent offerings, HFCA Act exposure, data rules, capital controls on moving IPO cash into PRC [20-F].
  • Investee valuation risk: Equity investments at 41% of total assets expose book value to mark-to-market losses.
  • Name confusion / reputational risk: Potential perceived association with the unrelated Ping An group could attract regulatory or legal challenge (no such action disclosed).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Jul 17, 2025IPO priced at US$6.00, 2.5M sharesLow end of range; small float
Jul 18, 2025Trading debut; closes US$3.3045% first-day decline signals weak demand
Jul 22, 2025IPO closes; governance policies adoptedFormal public-company governance in place
Aug 22, 2025Record date for EGM on name changeStrategic shift signaled within five weeks of IPO
Aug 27, 2025Hainan biotech WFOE formedFirst biomedical corporate step
Sep 12, 2025EGM approves rename to Ping An BiomedicalBrand association risk with unrelated Ping An group
Sep 26, 20256-K confirms ticker changeAdministrative
Sep 29, 2025H1 FY2025 interim results: revenue RMB18.2M (down 60%), gross lossBusiness deterioration disclosed
Sep 30, 2025PASW trading beginsAdministrative
Oct 1, 2025Share price around US$1.24Down about 79% from IPO price
Oct 14, 2025Leadership overhaulFounding family exits management
Nov 3, 2025Direct Booking Technology investmentCapital redeployed into equities
Nov 24–28, 2025Nasdaq bid-price deficiency noticeDelisting risk begins
Nov 28, 2025Consultant options granted (4.05M shares) and S-8 filedDilution; RMB12.96M deferred compensation
Jan 9, 2026Future Biotechnology Group memorandumHeadline US$90M of potential deals vs. tiny balance sheet
Jan 9, 2026Strategic investor share purchase agreements announcedBrings recognized internet-sector names onto register
Jan 30, 2026FY2025 20-F filedNet loss RMB12.8M; going-concern language
Feb 9–12, 2026100M-share placement at US$0.04 (US$4.0M)Roughly 5x share count increase at a deep discount to market
Mar 9, 2026AGM noticeDual-class and consolidation proposals
Mar 10, 2026567,000-share placement at US$0.15Minor
Mar 18–19, 2026AGM approves all five resolutionsControl entrenchment and reverse-split authority
Apr 1, 2026Form 3 filings by CFO and directorNo holdings reported
Apr 8, 2026CEO Form 3: 12.25M shares via INSPIRETECHOwnership disclosed
May 26–27, 2026Second 180-day Nasdaq compliance period granted to Nov 23, 2026Reverse split likely required
Jul 2–20, 2026Related-party trademark purchase (US$2.5M)Cash to Controlling Shareholder entity; about half of March 2026 cash and restricted cash
Jul 22, 2026Yuan Sheng Mei Yan cooperation agreementFirst commercial biomedical arrangement; shares fall about 11%
Aug 5–7, 2026Auditor change to Edston Global PACNo disagreements reported
Aug 18, 2026Share price about US$0.13Persistent sub-US$0.20 trading
Sep 11, 2026H1 FY2026 results: net income RMB4.83M on non-operating gainsHeadline profit; underlying loss
Sep 24, 2026Price about US$0.13; market cap about US$15.9M; 52-week range US$0.11–US$1.32 (Benzinga)Valuation baseline

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement (CNY): Revenue to Operating income: Revenue fell from CNY 18.2 Mn in H1 FY2025 to CNY 9.6 Mn in H1 FY2026.
Ping An Biomedical Co. Ltd. — Income Statement (CNY): Revenue to Operating income
Series (CNY Mn)H1 FY2025H1 FY2026
Revenue18.29.6
Gross profit-0.70.7
Selling and marketing0.21.7
General and administrative2.64.5
Credit loss provision (reversal)0.1-6.1
Operating income-3.60.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.